Milestone Pharmaceuticals appoints Joseph Papa to Board of Directors

Milestone Pharmaceuticals Inc.

Joseph Papa, CEO of Emergent BioSolutions, appointed director effective Sept 3, 2024; over 35 years pharma experience.
Papa will serve on Compensation Committee; receives $42,500 annual cash retainer and 80,000-share option grant.
2024 annual meeting results: all 7 director nominees elected; PricewaterhouseCoopers ratified as auditor.
Board committees updated: Fischer named Compensation Chair; Papa joins Compensation Committee.
Company advancing CARDAMYST (etripamil nasal spray) for PSVT towards potential FDA decision.

item 5.02 item 5.07 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Joeseph C. Papa

member of the Board

MIST · Milestone Pharmaceuticals Inc.

Effective: 2024-09-03
Filed: September 4, 2024, 7:59 PM ET

the Board of Directors (the “ Board ”) of Milestone Pharmaceuticals Inc. (the “ Company ”), upon the recommendation of the Nominating & Corporate Governance Committee of the Board, voted to elect Joeseph C. Papa as a member of the Board and as a member of the Board’s compensation committee (the “ Compensation Committee ”), effective as of September 3, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Joeseph C. Papa was elected as member of the Board at Milestone Pharmaceuticals Inc..

Action: elected
Role: member of the Board

Exact text from the filing

the Board of Directors (the “ Board ”) of Milestone Pharmaceuticals Inc. (the “ Company ”), upon the recommendation of the Nominating & Corporate Governance Committee of the Board, voted to elect Joeseph C. Papa as a member of the Board and as a member of the Board’s compensation committee (the “ Compensation Committee ”), effective as of September 3, 2024

View on SEC.gov

Milestone Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-096648

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.